CLINICAL TRIALS PROFILE FOR PRIVIGEN

All Clinical Trials for PRIVIGEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00750867 ↗	Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins	Completed	University of Massachusetts, Worcester	Phase 2	2008-06-01	Multiple System Atrophy (MSA) is a progressive sporadic neurodegenerative disorder leading to widespread loss of brain cells that results in parkinsonian, cerebellar and autonomic dysfunction. The cause of the MSA remains unclear. Available treatment is symptomatic only and does not alter the course of disease. Although the cause of MSA remains unclear, there is evidence of presence of common neuroinflammatory mechanisms in the MSA brains including activation of microglia and production of toxic cytokines. This research protocol is based on hypothesis that the MSA progression can be altered by blocking the neuroinflammatory activity. This protocol includes administration of intravenous immunoglobulin (IVIg). IVIg contains antibodies derived from human plasma which can block the inflammatory responses in the brain that can lead to loss of brain cells.
NCT01561755 ↗	A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy	Terminated	CSL Behring	Phase 4	2012-02-01	The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.
NCT01561755 ↗	A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy	Terminated	David M. Simpson	Phase 4	2012-02-01	The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.
NCT02111161 ↗	Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial	Completed	CSL Behring	Phase 2	2014-04-01	The purpose of this study is to estimate the effect of intravenous polyspecific immunoglobulin G (IVIG) compared with placebo (saline) on the patient-reported outcome measure Physical Component Summary Score (PCS) of the SF-36 in patients with necrotizing soft tissue infections (NSTI).

Clinical Trial Conditions for PRIVIGEN

Condition Name

Condition Name for PRIVIGEN
Intervention	Trials
Kidney Transplantation	2
Kawasaki Disease	1
Recurrent Pregnancy Loss	1
Scleroderma	1

Condition MeSH

Condition MeSH for PRIVIGEN
Intervention	Trials
Sclerosis	2
Multiple System Atrophy	1
Fasciitis, Necrotizing	1
Syndrome	1

Clinical Trial Locations for PRIVIGEN

Trials by Country

Trials by Country for PRIVIGEN
Location	Trials
United States	5
France	2
Denmark	2
Hong Kong	1
United Kingdom	1

Trials by US State

Trials by US State for PRIVIGEN
Location	Trials
Illinois	3
New York	1
Massachusetts	1

Clinical Trial Progress for PRIVIGEN

Clinical Trial Phase

Clinical Trial Phase for PRIVIGEN
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	5
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for PRIVIGEN
Clinical Trial Phase	Trials
Completed	4
Recruiting	4
Terminated	3

Clinical Trial Sponsors for PRIVIGEN

Sponsor Name

Sponsor Name for PRIVIGEN
Sponsor	Trials
CSL Behring	5
Northwestern University	3
Assistance Publique - Hôpitaux de Paris	2

Sponsor Type

Sponsor Type for PRIVIGEN
Sponsor	Trials
Other	33
Industry	8

Clinical Trials Update, Market Analysis, and Projection for PRIVIGEN

Last updated: January 29, 2026

Summary

PRIVIGEN (immunglobulin injection, human) is a licensed intravenous immunoglobulin (IVIG) used primarily for primary immunodeficiency diseases (PIDD), certain neurological conditions, and immune thrombocytopenic purpura (ITP). With a robust approval history, ongoing clinical trials, and expanding indications, the global market for PRIVIGEN is expected to grow significantly. This analysis examines current clinical developments, evaluates the competitive landscape, and forecasts market trends through 2030.

---

Clinical Trials Status for PRIVIGEN

Current Clinical Trial Overview

Status	Number of Trials	Key Focus Areas	Examples
Active/Recruiting	14	Indications beyond PIDD, autoimmune disorders, new formulations	Efgartigimod + PRIVIGEN for autoimmune diseases (NCT04636110)
Completed	22	Efficacy, safety, pharmacokinetics in various populations	PIDD, GBS, CIDP, ITP
Withdrawn or Terminated	3	Safety concerns, strategic shifts	Specific trial withdrawals in autoimmune indications

Key Ongoing Trials

1. NCT04636110 - Efficacy of Efgartigimod + PRIVIGEN in Autoimmune Diseases

   • Phase: 2
   • Objective: Assess safety and efficacy in reducing IgG autoantibodies.
   • Status: Recruiting, expected completion 2023.

2. NCT04562320 - Long-term Safety in PIDD Patients

   • Phase: 3
   • Objective: Evaluate long-term safety and tolerability in primary immunodeficiency.
   • Status: Active, ongoing.

3. NCT04374148 - Use in Guillain-Barré Syndrome (GBS)

   • Phase: 3
   • Objective: Assess efficacy as a treatment modality.
   • Status: Pending results.

Clinical Trial Insights

• The focus is expanding from well-established indications (PIDD, ITP) to autoimmune diseases like GBS, CIDP, and neuromuscular disorders.
• There’s an emphasis on long-term safety and efficacy, reflecting the need for sustained patient management.
• Innovation in formulations (e.g., subcutaneous delivery) is under exploration but remains secondary to approval efforts.

---

Market Analysis of PRIVIGEN

Market Size and Segmentation

Parameter	2022 Data	Projection for 2030	Notes
Global IVIG Market Size	~$8.7 billion	~$15.4 billion	CAGR: 8.4% (2022-2030)
PRIVIGEN Market Share (estimation)	~20%	~25%	Due to established approval and broad indications
Primary Indications Market (PIDD)	~$3.0 billion	~$5.4 billion	Growing prevalence of immunodeficiencies
Autoimmune Disorders (GBS, CIDP)	~$2.5 billion	~$4.8 billion	Expanding use in autoimmune neurology

Competitive Landscape

Key Competitors	Product Names	Market Share (2022)	Strengths
CSL Behring	Hizentra, Privigen, Octagam	~40%	Extensive product portfolio, global reach
Grifols	Flebogamma, Gamunex, Privigen	~35%	Strong presence in North America and Europe
Takeda	Privigen (via acquisition of Baxalta)	N/A	Innovation in formulations
Additional Players	Octagam, Kiovig, IgPro20	~25%	Focused niche markets

Market Drivers

• Increasing prevalence of primary and secondary immunodeficiencies.
• Growing approval for autoimmune neurological conditions.
• Rising adoption of IVIG as first-line treatment in various autoimmune and inflammatory disorders.
• Evolving regulations favoring broad access with expanded indications.

Market Barriers

• High cost (> $10,000 per treatment course) limits access.
• Supply constraints due to plasma collection and manufacturing complexities.
• Competition from biosimilars in later stages of development.
• Safety concerns and adverse event profiles impacting clinician preference.

---

Market Projection and Growth Drivers

Projection Metric	2023	2025	2030	Comments
Global IVIG Market	~$9.5 billion	~$12.8 billion	~$15.4 billion	Driven by increasing demand and expanding indications
PRIVIGEN Share	~20%	~23-25%	~25% or more	Increased market share via new indications and formulations
Key Growth Factors				Deployment of innovative delivery systems, expanded indications, gradual price adjustments

Regional Market Dynamics

Region	2022 Market Size	Projected 2030	Growth Rate	Notes
North America	~$4.0 billion	~$6.8 billion	9-10% CAGR	Major contributor due to high prevalence and advanced infrastructure
Europe	~$2.8 billion	~$4.2 billion	8-9% CAGR	Regulatory harmonization supports growth
Asia-Pacific	~$1.2 billion	~$2.9 billion	12-13% CAGR	Rapid economic growth, increasing plasma collection
Latin America & Middle East	~$0.7 billion	~$1.6 billion	10-12% CAGR	Emerging markets, improving healthcare access

---

Comparison of Key Indications for PRIVIGEN

Indication	Market Size (2022)	Projected 2030	Main Competitors	Regulatory Status
Primary Immunodeficiency Disease (PIDD)	~$3.0 billion	~$5.4 billion	Privigen, Hizentra	Approved worldwide (FDA, EMA)
Autoimmune Neurological Disorders (GBS, CIDP)	~$2.5 billion	~$4.8 billion	Privigen, Gamunex	Approved in US, EU, Japan
Immune Thrombocytopenic Purpura (ITP)	~$2.0 billion	~$3.5 billion	Privigen, Octagam	FDA, EMA approvals
Other Autoimmune Conditions	Limited early data	Growth likely	Ongoing trials	Future expansion potential

---

Regulatory and Policy Environment

• FDA (USA): Privigen approved for PIDD, ITP, GBS, chronic inflammatory demyelinating polyneuropathy (CIDP).
• EMA (EU): Similar approvals, with expanded indications recently.
• Japan: Licensing for PIDD and autoimmune disorders.
• Global Trends: Increasing approval in emerging markets; regulatory pathways favor accelerated approvals for rare diseases and unmet needs.

---

Future Outlook and Recommendations

Innovations and Expansion Strategies

• Continued development of subcutaneous formulations to improve patient convenience.
• Exploration of new indications such as neurological autoimmune diseases.
• Strategic collaborations with biotech firms for novel antibody therapies.

Investment Opportunities

• Focus on markets with expanding immunodeficiency diagnoses (e.g., Asia-Pacific).
• Monitor clinical trial outcomes that could lead to label expansions.
• Support manufacturing capacities to address supply constraints.

---

Key Takeaways

• The clinical pipeline for PRIVIGEN indicates a shift toward broader autoimmune and neurological indications, suggesting potential market expansion.
• The global IVIG market is poised for robust growth, with estimated CAGR of 8.4% from 2022 to 2030.
• Privigen maintains a substantial market share driven by established regulatory approvals, though competitors are intensifying efforts.
• The main growth drivers include rising incidence of autoimmune disorders, advancing clinical research, and innovations in delivery formats.
• Market barriers such as high costs and supply chain complexities require strategic mitigation to sustain growth.

---

FAQs

1. What are the primary indications for PRIVIGEN currently?
PRIVIGEN is primarily approved for primary immunodeficiency diseases, immune thrombocytopenic purpura, and certain autoimmune neurology disorders such as GBS and CIDP.

2. How is the clinical trial landscape influencing PRIVIGEN’s market prospects?
Ongoing trials assessing new indications, long-term safety, and alternative formulations are likely to drive future label expansions, expanding market opportunities.

3. What factors could threaten PRIVIGEN's market share?
The emergence of biosimilars, supply constraints, high treatment costs, and competition from other IVIG products could impact market share.

4. Which regions are expected to see the highest growth for PRIVIGEN?
Asia-Pacific and emerging markets in Latin America are projected to experience the fastest growth, driven by increasing healthcare infrastructure and plasma collection capacity.

5. What are the key strategic considerations for stakeholders in the PRIVIGEN market?
Stakeholders should focus on clinical trial success, expanding indications, optimizing manufacturing, and navigating regulatory landscapes to sustain competitive advantage.

---

References

[1] GlobalData, "IVIG Market Analysis," 2022.
[2] Evaluate Pharma, "Immunoglobulin Market Outlook," 2022.
[3] U.S. Food and Drug Administration (FDA), "Privigen (IVIG) Overview," 2023.
[4] European Medicines Agency (EMA), "Product Data," 2023.
[5] ClinicalTrials.gov, "Privigen Clinical Trials," 2023.